Sagimet Biosciences Inc.
Clinical-stage biopharma developing FASN inhibitors for MASH, acne, and cancer.
SGMT | NDAQ
Overview
Corporate Details
- ISIN(s):
- US7867001049
- LEI:
- Country:
- United States of America
- Address:
- 155 BOVET RD., SUITE 303, 94402 SAN MATEO
- Website:
- https://sagimet.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors. These inhibitors are designed to treat dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The company's pipeline includes its lead product candidate, denifanstat, and another candidate, TVB-3567. Sagimet is exploring the therapeutic potential of its FASN inhibitors in treating metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer, where dysregulation of fatty acid metabolism plays a key role.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Sagimet Biosciences Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sagimet Biosciences Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sagimet Biosciences Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
